Get started

Adverum Biotechnologies, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

ADVM chart

Key stats

Market capitalization
169.668MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.33USD
Net income
−154.536MUSD
Revenue
—
Shares float
100.993M
Beta
1.06

About Adverum Biotechnologies, Inc.

Sector
Health Technology
CEO
Laurent Fischer
Headquarters
Redwood City
Website
adverum.com
Employees
123
Founded
2006
ISIN
US00773U1088

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Ideas

ADVM | Adverum Biotechnologies, Inc. Healthcare US STOCKSBullish trend 📉 Stock: ADVM | Adverum Biotechnologies, Inc. Healthcare | Biotechnology | USA | NASDAQ Trend Analysis: The stock's price has been consistently following a uptrend characterized by higher highs and higher lows. Traders may look for buying opportunities as the stock approaches the b
Long
Adverum Biotechnologies, Inc.On the above bi-Weekly chart price action has corrected over 90% since June 2020. A number of reasons now exist to be bullish , including: 1) A strong buy signal prints (not shown). 2) Regular bullish divergence . Multiple oscillators printing divergence. 3) Price action confirms support on past re
Long
4
time to add target 2.25time to add target 2.25 stoploss 1.13..Adverum is moving forward with its eye disease gene therapy that caused headaches in April 2021, but is doing so with fewer staff on board. The biotech is laying off 78 employees, or about 38% of its workforce, in order to conserve cash and keep the lights on
Long
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collabo
Long
Adverum Biotechnologies Inc 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collabo
Long

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers